U.S. Antitrust Enforcement in 2013: Where Are We Going, and Why? CPI Antitrust Chronicle (January 2013 (1))

Making Victims Whole - A Restitution Approach to Cartel Damages, Concurrences 1 – 2012 (2012)

A Trip Around the Cartel Victims Remedy Buffet, The CPI Antitrust Chronicle (November 2011(1))

Innovation Market Theory and Practice: An Analysis and Proposal for Reform, Competition Policy International, Spring 2011, Vol. 7, No.1 (2011)

U.S. Antitrust 2025:  How Have we Handled the Bulletproof Cartels? The CPI Antitrust Journal (December 2010 (2))

The Astra Zeneca Decision in the General Court: Some Basic Observations and a Few Interesting Questions,The CPI Antitrust Journal (September 2010 (2))

Private Antitrust Litigation in the European Union – Why Does the EC Want to Embrace What the U.S. FTC is Trying to Avoid? , Global Competition Litigation Review (Issue 2, 2010) 69

The Intel Cases – Legal Convergence or Leaps of Faith? The CPI Antitrust Journal (February 2010(2))

Some Thoughts on Article 82 Jurisprudence – If the Government Always Wins, Should Private Litigants Win as Well?, Global Competition Policy (August 2009, Release 1)

Gatekeeper Issues: Seeing What is In Front of You – A Transatlantic Lesson in Two Cases, 2009, Issue 4, European Competition Law Review 189

Solving the Wrong Problem - The Preliminary Report on the EC Pharmaceutical Sector Inquiry: What Have We Really Learned?  Global Competition Policy (February 2009, Release 2)

The EU’s Drug Problem – Can the U.S. Provide an Answer?  Competition Law Insight (10 February 2009)

Monopolization/Abuse of Dominance and the Research Based Pharmaceutical Industry – The Chilling Effect of Uncertain Rules of Enforcement, in B. Hawk (ed.)  International Antitrust Law & Policy, 2008 Fordham Competition Law Institute, Chapter 14 (2009)

The 2008 EC Sector Inquiry Regarding Pharmaceuticals: What Does It Mean From a Research-Based Company Perspective, Global Competition Policy (November 2008)

An Effective, Practical Approach to International Competition Law Compliance, Volume 1, Issue 3, International In-House Counsel Journal 499 (2008)

The EC Sector Inquiry Regarding Pharmaceuticals: Some Thoughts from a U.S. Perspective, Global Competition Policy (February 2008)

Private Damages Actions: A U.S. Perspective on Importing U.S. Damages Actions to the EU, eCCP (October 2007)

Antitrust Treatment of Pharmaceutical Patent Settlements: The Need for Context and Fidelity to First Principles, 15 Fed. Cir. B.J. 617 (2006) [With Will Tom]

E. Disner, Antitrust for Business: Questions and Answers (1989) – Contributing Editor

On Judgments and Settlements in Antitrust Cases: When Should Damages Be Trebled?  56 St. John’s L, Rev. 1 (1981)

Backhauling, A Legal Justification, 15 New England L. Rev. 799 (1980)

Handling the “News”: A Proposed Approach for the Federal Trade Commission, 21 Ariz. L. Rev. 1021 (1980)

The Actions of the Antitrust Plaintiff:  Law, Policy and a Modest Proposal, 16 Duquesne L. Rev. 307 (1980)

Certified Questions in the Supreme Court: In Defense of an Option, 83 Dickinson L. Rev. 31 (1978)

Vouching to Warranties of Quality: A Legal Anachronism?  55 J. Urban Law, 73 (1977)

Churches, Members, and the Role of the Courts: Towards a Contractual Analysis, 51 Notre Dame Lawyer 545 (1976)

Structures of American Military Justice, 125 U. Pa. L. Rev. 397 (1976)

Comment: The Environmental Court Proposal: Requiem, Analysis and Counterproposal, 123 U. Pa. L. Rev. 676 (1975)